RxDoctor Payments DataLook up a doctor →

Kelly Holmes

Family · Hickory, NCNPI 1548991565

Payments from drug & device makers

$55,488in general payments, 2019–2025

Across 1,127 payments — averaging $49.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$34K
  • TG Therapeutics, Inc.$3K
  • AbbVie$2K
  • MDD US Operations, LLC$2K
  • Abbott$1K
  • EMD Serono, Inc.$1K
  • plus $12K from 54 others

What the payments were for

  • Consulting fees$1,8103%
  • Speaking & faculty fees$27,66150%
  • Travel & lodging$5,47710%
  • Food & beverage$19,79536%
  • Education$7451%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.244$33,997
TG Therapeutics, Inc.37$3,280
AbbVie166$2,198
MDD US Operations, LLC43$1,595
Abbott7$1,302
EMD Serono, Inc.27$1,170
Novartis61$1,149
UCB, Inc.45$938
Acadia Pharmaceuticals Inc39$788
Jazz Pharmaceuticals Inc.22$762
Livanova USA, Inc.9$691
Pfizer51$600
Neurelis, Inc.42$576
Neurocrine Biosciences, Inc.32$550
Lilly USA, LLC34$490
Biogen23$445
Lundbeck LLC28$415
Argenx US, Inc.17$359
Sumitomo Pharma America, Inc.14$279
AstraZeneca(2 entities)9$264
Takeda Pharmaceuticals U.S.A., Inc.11$261
SK Life Science, Inc.13$243
Bristol Myers Squibb12$231
Eisai Inc.9$198
Impel Pharmaceuticals Inc.20$195
Merz Pharmaceuticals, LLC7$159
Idorsia Pharmaceuticals US Inc8$155
Sanofi2$154
Amneal Pharmaceuticals LLC7$144
Amgen6$120
Averitas Pharma Inc.6$119
Otsuka America Pharmaceutical, Inc.6$118
Octapharma USA, Inc.5$105
Corium, LLC6$103
Acorda Therapeutics, Inc5$100
Inspire Medical Systems, Inc.2$94
Aucta Pharmaceuticals, Inc.6$91
ANI Pharmaceuticals, Inc.4$88
Azurity Pharmaceuticals, Inc.4$88
Sandoz3$79
Impel Pharmaceuticals LLC4$78
Genentech USA, Inc.3$78
Kyowa Kirin, Inc.3$75
Harmony Biosciences LLC2$66
E.r. Squibb & Sons, L.L.C.2$58
Axsome Therapeutics, Inc.3$58
Vanda Pharmaceuticals Inc.2$42
GRT US Holding, Inc.2$40
GE HealthCare2$36
Boston Scientific1$33
Medtronic1$31
Biohaven Pharmaceutical Holding Company Ltd.1$30
Johnson & Johnson1$26
Kedrion Biopharma, Inc.1$22
Mallinckrodt Hospital Products Inc.1$21
Avadel CNS Pharmaceuticals, LLC1$21
Fisher & Paykel Healthcare Inc1$17
Almatica Pharma LLC1$17
Upsher-smith Laboratories LLC1$15
Sunovion Pharmaceuticals Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$55,488 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$214,012
Medicare patients
239
Services billed
14,496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine67$715,781
BetaseronInterferon Beta-1b24$232,902
ZeposiaOzanimod Hydrochloride12$107,212
NuplazidPimavanserin Tartrate16$98,748
Nurtec OdtRimegepant Sulfate54$71,398
Ajovy AutoinjectorFremanezumab-Vfrm55$47,696
QuliptaAtogepant40$47,203
NamzaricMemantine Hcl/Donepezil Hcl35$42,956
VraylarCariprazine Hcl28$41,122
BriviactBrivaracetam25$40,012
GocovriAmantadine Hcl18$35,580
UbrelvyUbrogepant17$25,708
XcopriCenobamate13$24,976
Dalfampridine ErDalfampridine24$14,346
Aimovig AutoinjectorErenumab-Aooe19$14,322

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$33,997$715,78167 claims
AbbVieQulipta, Namzaric, Vraylar, Ubrelvy, Botox$2,198$182,173150 claims
E.r. Squibb & Sons, L.L.C.Zeposia$58$107,21212 claims
Acadia Pharmaceuticals IncNuplazid$788$98,74816 claims
PfizerNurtec Odt$600$71,39854 claims
UCB, Inc.Briviact$938$40,01225 claims
MDD US Operations, LLCGocovri$1,595$35,58018 claims
SK Life Science, Inc.Xcopri$243$24,97613 claims
Eisai Inc.Fycompa$198$12,77111 claims
Lilly USA, LLCReyvow$490$10,23714 claims
Upsher-smith Laboratories LLCTopiramate$15$1,11374 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →